Exemestane and Telmisartan Interaction
Exemestane and Telmisartan have a potentially harmful interaction with 75% confidence. Both Exemestane and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Both compounds affect the heart, so monitoring these systems is recommended.
Compound Profiles
Exemestane
Steroidal Aromatase Inhibitor | Irreversible Estrogen Control
Exemestane functions as a mechanism-based (suicide) inhibitor of aromatase (cytochrome P450 19A1). Due to its steroidal structure, exemestane is recognized by aromatase as a substrate analogue and enters the enzyme's active site.
View full profileTelmisartan
Angiotensin II Receptor Blocker | Cardiac Protection On Cycle
Telmisartan selectively blocks the angiotensin II type 1 (AT1) receptor, preventing angiotensin II from exerting its vasoconstrictive, aldosterone-secreting, and pro-fibrotic effects. By antagonizing AT1, telmisartan lowers systemic vascular resistance and blood pressure while simultaneously reducing pathological cardiac and vascular remodeling.
View full profileCombined Organ Load
Shared Safety Flags
Frequently Asked Questions
Can I take Exemestane with Telmisartan?
Combining Exemestane with Telmisartan is not recommended. Both Exemestane and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Is Exemestane and Telmisartan safe together?
This combination carries significant risk. Both Exemestane and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.
What are the interactions between Exemestane and Telmisartan?
Both Exemestane and Telmisartan carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 75% confidence and is inferred from pharmacological mechanism analysis.
How should I time Exemestane and Telmisartan?
Exemestane has a half-life of ~24 hours and Telmisartan has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.
This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.